who demonstrated superior OS for IDHmut AML patients treated with alloHCT in CR1 [46], but also contrary to previous studies associating IDH mutations with higher rates of relapse after alloHCT [30]. This evidence concerns the gene IDH1 and acute myeloid leukemia.